Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant

A. Madhi, Shabir; L. Baillie, Vicky; Cutland, Clare; Voysey, Merryn; Koen, Anthonet; Fairlie, Lee; D. Padayachee, Sherman; Dheda, Keertan; Barnabas, Shaun; Bhorat, Qasim; Briner, Carmen; Kwatra, Gaurav; Ahmed, Khatija; K. Aley, Parvinder; Bhikha, Sutika; N. Bhiman, Jinal; E. Bhorat, As’ad; du Plessis, Jeanine; Esmail, Aliasgar; Groenewald, Marisa; Horne, Elizea; Hwa, Shi-Hsia; Jose, Aylin; Lambe, Teresa; Laubscher, Matt; Malahleha, Mookho; Masenya, Masebole; Masilela, Mduduzi; McKenzie, Shakeel; Molapo, Kgaogelo; Moultrie, Andrew; Oelofse, Suzette; Patel, Faeezah; Pillay, Sureshnee; Rhead, Sarah; Rodel, Hylton; Rossouw, Lindie; Taoushanis, Carol; Tegally, Houriiyah; Thombrayil, Asha; van Eck, Samuel; Kurt Wibmer, Constantinos; M. Durham, Nicholas; J. Kelly, Elizabeth; Villafana, Tonya; C. Gilbert, Sarah; J. Pollard, Andrew; de Oliveira, Túlio; L. Moore, Penny; Sigal, Alex; Izu, Alane

doi:10.1056/nejmoa2102214

Public

Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant

Published in New England Journal of Medicine • Mar 16, 2021

Authors:

Shabir A. Madhi

Vicky L. Baillie

Clare Cutland

Abstract

BACKGROUND: Assessment of the safety and efficacy of vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in different populations is essential, as is investigation of the efficacy of the vaccines against emerging SARS-CoV-2 variants of concern, including the B.1.351 (50...

Subject

Coronavirus disease 2019 (COVID-19)

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

2019-20 coronavirus outbreak

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!